[Experimental and clinical studies on @entity10188 ( @entity798 - XXXX ) granules in the pediatric field].

@entity1 @entity115 @entity798 @entity7100 @entity281 @entity10188 @entity21830 @entity1729 @entity293 @entity9103
Fundamental and clinical studies have been performed on the @entity10188 granules (combination of @entity115 ( @entity21830 ) and @entity798 ( @entity9103 ) in 2: 1 ratio) in the pediatric field. In bacteriological studies a potentiated antibacterial activity of @entity10188 was recognized against @entity21830 -resistant and beta-lactamase producing clinical isolates. The pharmacokinetics of the @entity10188 granules were studied at dose levels from 10 to 20 mg/kg. The peak serum concentrations of @entity21830 and CVA achieved approximately 1 hour after dosing were 4.29-9.55 micrograms/ml and 3.87-4.78 micrograms/ml, respectively. The serum half-life was found to be 0.90-1.31 hours for @entity21830 and 1.01-1.22 hours for CVA. Six-hour urinary excretion rates were 29.5-62.6% for @entity21830 and 12.6-37.9% for CVA. In the clinical studies, the @entity10188 granules were administered to 36 pediatric @entity1 (15 with @entity1729 , 10 with @entity293 and 11 with skin or soft tissue @entity281 , etc.) at dose levels of 30-50 mg/kg/day. Clinical results in all cases were excellent or good. In particular, good bacterial and clinical effects were obtained against @entity281 caused by beta-lactamase producing @entity21830 -resistant strains except @entity7100 1 strain. No adverse reactions or abnormal laboratory findings were recognized in any @entity1 .
